The Natick, Mass.-based medical device giant said it will pay the settlement in cash using a reserve set aside for one of the lawsuits.
Cordis and Norman Noble Inc. filed the appeal in the U.S. Court of Appeals for the Federal Circuit. Spectralytics had sued the pair in July 2005 in the U.S. District Court for Minnesota, alleging infringement of a patent for a “Laser Cutting Tool for Cutting Elongated Hollow Workpieces.”
A prominent Ohio cardiologist with ties to Massachusetts is joining the board of Endovalve, a New Jersey-based mitral valve repair firm, MedCity News reported.
Marc Gillinov, head of the Cleveland Clinic’s Center for Atrial Fibrillation and a co-founder of Wilmington, Mass.-based Viacor, was named to Endovalve’s scientific advisory board.
It looks as though Boston Scientific Corp. might have left its heart (and some business) in San Francisco.
To say its been a rough week at the annual Transcatheter Cardiovascular Therapeutics meeting would be a grotesque understatement, as the Natick-based coronary stent colossus suffered a series of high-profile setbacks at the annual meeting of thousands of cardiologists from around the world.
A small version of Cordis Corp.‘s Cypher drug-eluting stent won approval from the Food & Drug Administration for treating blockages in small blood vessels.
The Bridgewater, N.J.-based Johnson & Johnson subsidiary said the federal watchdog’s approval of its 2.25mm Cypher sirolimus-eluting coronary stent was based on a quartet of studies comparing it to bare-metal stents.
Medtronic said the three-year results from the Endeavor IV trial comparing its zotarolimus‐eluting stent and BoSci’s paclitaxel‐eluting stent in 1,548 patients show a nearly 50 percent reduction in the risk of heart attack or cardiac death with the Endeavor stent.
Boston Scientific Corp. enrolled more than 1,500 patients in the Platinum clinical trial of its Promus Element drug-eluting stent, two months ahead of schedule, setting the stage for approval applications to the Food & Drug Administration and the Japanese Ministry of Health, Labor and Welfare.
The Natick, Mass.-based medical devices giant said the workhorse trial is a global, randomized, pivotal controlled study of its platinum chromium Promus Element everolimus-eluting stent involving 1,532 patients at more than 140 sites worldwide.